Outset Medical, Inc. (OM): Results of Operations and Financial Condition
Outset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 om-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA – August 6, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialys
How this was made
The 30-second read
Why it matters
Traders can update models using the reported revenue mix, gross margin expansion, cash position, and the newly signed three-year $40M HCA Healthcare refresh agreement.
Market read
The filing combines an earnings-style datapoint set (revenue, margins, cash burn) with a concrete contract that should improve backlog visibility.
What to watch
Investors may underweight the product gross margin deterioration (48.9% to 46.1%) and the sizable service gross margin swing, which could reverse if service profitability normalizes.
Background
This is an SEC Form 8-K with Exhibit 99.1 covering Outset Medical’s Q2 2026 financial results and 2026 guidance.
Ticker impact
Outset Medical reported Q2 2026 results and reiterated 2026 revenue guidance of $125M to $130M, plus a new HCA refresh agreement.
Near-term bias modestly positive if investors focus on gross margin expansion and the new refresh agreement; downside risk if cash burn and product margin weakness dominate.
The filing provides multiple decision-useful datapoints: gross margin up to 42%, guidance reiterated, and a specific $40M contract. However, product revenue declined 5% and cash used was $9.5M, limiting upside conviction.
Market effects
Dialysis technology and medtech-adoption narratives may get a small read-through from margin improvement and recurring consumables/service mix.
Limited, primarily company-specific given the US-focused HCA Healthcare agreement.
Low, as the disclosed contract and guidance are US-centric and not tied to global regulatory or supply shocks.
Counterpoint
Margin expansion may be driven by service mix and one-off cost dynamics, while product revenue decline and cash burn suggest growth quality is still uneven.
Key entities
- issuerOutset Medical, Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and reiterating 2026 guidance.
- customer_partnerHCA Healthcare
Signed a three-year, $40M agreement to refresh Outset’s Tablo systems across its health system.
